WallStSmart
MGNX

MacroGenics Inc

NASDAQ: MGNX · HEALTHCARE · BIOTECHNOLOGY

$3.08
+4.76% today

Updated 2026-04-30

Market cap
$193.86M
P/E ratio
P/S ratio
1.30x
EPS (TTM)
$-1.18
Dividend yield
52W range
$1 – $4
Volume
1.1M

MacroGenics Inc (MGNX) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+41.5%
Last 4 quarters
Revenue YoY growth
+132.5%
Most recent quarter
EPS YoY growth
+73.1%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+2.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+5.3%
2025-11-12
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-19$-0.22+18.4%$1.70$1.70+0.0%
2025-11-12$0.27+165.9%$1.52$1.60+5.3%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.27$-0.22+18.4%$41.23M+132.5%
2025-09-30$-0.41$0.27+165.9%$72.84M-34.2%
2025-06-30$-0.46$-0.57-23.9%$22.24M+106.0%
2025-03-31$-0.69$-0.65+5.8%$13.19M+44.9%
2024-12-31$-0.59$-0.82-38.6%$17.73M+65.4%
2024-09-30$0.21$0.90+328.6%$110.71M+964.8%
2024-06-30$-0.59$-0.89-50.8%$10.80M-17.8%
2024-03-31$-0.64$-0.84-31.2%$9.10M-62.8%
2023-12-31$-0.15$-0.75-400.0%$10.72M
2023-09-30$-0.10$0.28+380.0%$10.40M
2023-06-30$-0.52$-0.69-32.7%$13.14M
2023-03-31$0.45$-0.61-235.6%$24.50M
2022-12-31$0.10$0.21+110.0%

Frequently asked questions

Has MacroGenics Inc beaten earnings estimates?
MacroGenics Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +41.5% over the last 4 quarters.
How does MGNX stock react to earnings?
MGNX stock has moved an average of +2.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is MacroGenics Inc's revenue growth rate?
MacroGenics Inc reported year-over-year revenue growth of +132.5% in its most recent quarter, with EPS growing +73.1% year-over-year.